The Alzheimers Disease Partnering 2007-2013 provides understanding and access to the alzheimers disease partnering deals and agreements entered into by the worlds leading healthcare companies .
The report provides an analysis of alzheimers disease partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors alzheimers disease technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered contract documents provide this insight where press releases do not.
This data driven report contains over 190 links to online copies of actual alzheimers disease deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partners flexibility on a wide range of important issues, many of which will have a significant impact on each partys ability to derive value from the deal.
The initial chapters of this report provide an orientation of alzheimers disease partnering trends.
Chapter 1 provides an introduction to the report, whilst
Chapter 2 provides an overview of the trends in alzheimers disease partnering since 2007, including a summary of deals by industry sector, stage of development, deal type, and technology type. Numerous tables provide outline financial trends.
Chapter 3 provides an overview of the leading alzheimers disease deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive directory of alzheimers disease partnering deals signed and announced since 2007. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of dementia technologies and products.
Alzheimers Disease Partnering 2007-2013 is intended to provide the reader with an in-depth understanding and access to alzheimers disease trends and structure of deals entered into by leading companies worldwide.
This data driven report includes:
- Trends in alzheimers disease dealmaking in the biopharma industry since 2007
- Access to summary headline, upfront, milestone and royalty data
- The leading dementia deals by value since 2007
In Alzheimers Disease Partnering 2007-2013, the available deals are listed by:
- Headline value
- Upfront payment value
- Royalty rate value
- Company A-Z
- Industry sector
- Stage of development at signing
- Deal component type
- Technology type
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Table of Content
Chapter 1 Introduction
Chapter 2 Trends in alzheimer\'s disease partnering
2.2. Alzheimer\'s disease partnering over the years
2.3. Bigpharma alzheimer\'s disease dealmaking activity
2.4. Alzheimer\'s disease partnering by deal type
2.5. Alzheimer\'s disease partnering industry sector
2.6. Alzheimer\'s disease partnering by stage of development
2.7. Alzheimer\'s disease partnering by technology type
2.8. Disclosed financial deal terms for alzheimer\'s disease partnering
2.8.1 Alzheimer\'s disease headline values
2.8.2 Alzheimer\'s disease upfront payments
2.8.3 Alzheimer\'s disease milestone payments
2.8.4 Alzheimer\'s disease royalty rates
Chapter 3 Leading alzheimer\'s disease deals
3.2. Top alzheimer\'s disease deals by value
3.3. Top alzheimer\'s disease deals involving bigpharma
Chapter 4 Dealmaking directory
4.2. Company A-Z
4.3. By deal type
4.4. By industry sector
4.5. By stage of development
4.6. By technology type
Diagnostic - companion
In vitro models
Chapter 5 Partnering resource center
5.1. Online partnering
5.2. Partnering events
5.3. Further reading on dealmaking
Appendix 1 Deal type definitions
About Wildwood Ventures
Recent titles from CurrentPartnering
Order Form Reports
List of Chart
Figure 1: Alzheimer\'s disease partnering since 2007
Figure 2: Bigpharma top 50 alzheimer\'s disease deals 2007 to 2011
Figure 3: Bigpharma alzheimer\'s disease deal frequency 2007 to 2011
Figure 4: Alzheimer\'s disease partnering by deal type since 2007
Figure 5: Alzheimer\'s disease partnering by industry sector since 2007
Figure 6: Alzheimer\'s disease partnering by stage of development since 2007
Figure 7: Alzheimer\'s disease partnering by technology type since 2007
Figure 8: Alzheimer\'s disease deals with a headline value
Figure 9: Alzheimer\'s disease deals with upfront payment values
Figure 10: Alzheimer\'s disease deals with milestone payments
Figure 11: Alzheimer\'s disease deals with royalty rates, %
Figure 12: Top alzheimer\'s disease deals by value since 2007
Figure 13: Top alzheimer\'s disease deals signed by bigpharma value since 2007
Figure 14: Online partnering resources
Figure 15: Forthcoming partnering events
Figure 16: Deal type definitions
Make an enquiry before buying this Report
Please fill the enquiry form below.